On the stock market since 2011, it operates in the world of health and science. It has 127 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $9.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 36 buys and 14 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $4.00 — 345% above today’s price.
A loss of $48.8M against $9.0M in annual sales.
The stock sits at $0.90. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, NSPR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NSPR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (8/100) says the stock isn’t cheap.